Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Research

| More

IPO Review - Krishna Institute of Medical Sciences Ltd - ICICI Direct

Posted On: 2021-06-16 15:06:11 (Time Zone: UTC)


Started by renowned cardiothoracic surgeon Dr Bhaskara Rao Bollineni in 2000, Krishna Institute of Medical Sciences (KIMS) is one of the largest corporate healthcare groups in Andhra Pradesh and Telangana. As of FY21, KIMS operates nine multi-specialty hospitals with a bed capacity of 3,064, including over 2,500 operational beds. It offers a comprehensive range of healthcare services across 25 specialties and super specialties. The company has a strategic focus on the southern India healthcare market where it has a strong understanding of regional nuances, customer culture and the mindset of medical professionals and where there is significant and growing need for quality and affordable healthcare services. In FY21, KIMS recorded ARPOB of Rs. 20,609, a bed occupancy rate of 78.60% and an ALOS of 5.53 days, on an aggregate basis.

Investment Rationale

Strong hospital chain pedigree in AP, Telangana

KIMS owns one of the largest hospital chains in AP and Telangana. It reported Rs. 1340.1 crore of revenues and Rs. 381.0 crore of adjusted EBITDA in FY21, the highest in AP and Telangana. It has 3,064 beds as of 9MFY21, which is 2.2x more beds than the second largest provider in these regions.

Strong financial track record

KIMS has achieved healthy profitability in both Tier I and Tier II, III markets by identifying markets with significant underserved healthcare demand and delivering quality healthcare services at affordable prices, which, in turn, drives patient volumes. As of FY21, KIMS' debt-to-adjusted EBITDA ratio was 0.71x and gearing ratio was 0.31x compared to industry range of 0.1-5.2x. It has achieved strong free cash flow by effectively managing capex. KIMS is one of only three hospitals in India that are rated AA by Crisil.

For details, click on the link below: Link to the report


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.


Other Headlines:

Maintain BUY on Gateway Distriparks - Upbeat outlook with expected commencement of DFC - HDFC Securities

Maintain ADD on Colgate Palmolive - Steady growth, buoyant margins - HDFC Securities

Ajanta Pharma - Downgraded to ADD - India shines, margins a tad lower - HDFC Securities

Maintain REDUCE on ABB India - Capex recovery awaited - HDFC Securities

Tech Mahindra - Healthy deal wins - HDFC Securities

SRF Ltd - Technical textiles garners high realisation - HDFC Securities

UTI Asset Management Company - Tailwinds galore! - HDFC Securities

Sagar Cements - Strong show; capacity set to increase 43% in Sep-21 - HDFC Securities

Maintain ADD on Radico Khaitan - Beat in volumes, remain constructive - HDFC Securities

Mahindra Lifespaces - Mixed performance - HDFC Securities

Indus Towers - Q1 FY22 first cut - YES Securities

Tech Mahindra - Q1 FY22 first cut - YES Securities

TVSL - Q1 FY22 first cut - YES Securities

Orient Electric - Q1 FY22 first cut - YES Securities

Security and Intelligence Services (SIS) - Q1FY22 Concall Highlights - YES Securities

LIC Housing - Q1 FY22 first cut - YES Securities

Home First - Q1 FY22 first cut - YES Securities

Colgate-Palmolive (India) - Q1 FY22 Result Report - YES Securities

Ajanta Pharma - Q1 FY22 Result Report - YES Securities

Sagar Cements Ltd - Q1 FY22 Result Report - YES Securities

CCL Products (India) - Q1 FY22 Result Report - YES Securities

UTI AMC - Q1 FY22 Result Report - YES Securities

Dalmia Bharat Ltd - Q1 FY22 Result Report - YES Securities

Mahanagar Gas Ltd - Q1 FY22 Result Report - YES Securities

Dwarikesh Sugar - Q1FY22 First Cut - ICICI Direct

Tech Mahindra - Q1FY22 First Cut - ICICI Direct

PVR Ltd - Q1FY22 First Cut - ICICI Direct

EPL Ltd - Q1FY22 First Cut - ICICI Direct

Q1FY22 Result Update - TCI Express - ICICI Direct

Q1FY22 Result Update - Sagar Cements - ICICI Direct

Solar Industries - Q1FY22 First Cut - ICICI Direct

Indus Towers (erstwhile Bharti Infratel) - Q1FY22 First Cut - ICICI Direct

Q1FY22 Result Update - Mahindra Logistics - ICICI Direct

Q1FY22 Result Update - Maruti Suzuki - ICICI Direct

Q1FY22 Result Update - Mold-Tek Packaging - ICICI Direct

Q1FY22 Result Update - Nestlé India - ICICI Direct

Q1FY22 Result Update - Coforge Ltd - ICICI Direct

Q1FY22 Company Update - Birlasoft Ltd - ICICI Direct

Colgate Palmolive - Q1FY22 First Cut - ICICI Direct

Q1FY22 Result Update - Granules India - ICICI Direct

Q1FY22 Company Update - Pfizer Ltd - ICICI Direct

Jyothy Lab - Q1FY22 First Cut - ICICI Direct

Dalmia Bharat - Strong performance; embarks on major expansion - HDFC Securities

Maintain BUY on Teamlease Services - Future bright - HDFC Securities

Maintain REDUCE on Nestle India - Beat on revenue, a miss in margin - YES Securities

Tech Mahindra Q1FY22RU - First cut - YES SECURITIES

Maruti Suzuki - A weak quarter, CNG variants to ramp up in Q2FY22 - HDFC Securities

Taro Q1 FY22 result - key highlights - YES Securities

Tata Coffee - 1Q results - YES Securities

MSIL - Q1 FY22 results - YES Securities


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020